The efficacy and tolerability of two combinations, namely 50 mg @entity1482 + 20 mg @entity1483 (SF) or 50 mg @entity1482 + 5 mg @entity69718 (SB), were compared in a randomised intraindividual trial in 22 @entity1 with @entity712 . The parameters used were: weight, ankle- and @entity291 -circumference, blood pressure, resting pulse, resting ECG, spirometry and blood chemistry. The physicians' judgement of the success of treatment was also recorded. Clinical symptoms improved clearly in both groups and in most cases there was significant improvement of the various parameters. The trend towards improvement was more apparent with SF. The physicians considered SF to be more effective in 12 cases compared to one case with SB. In all other cases both treatments were considered equally effective. The blood chemistry data showed relevant differences: serum- @entity972 levels were less scattered with SF and showed a - desirable - shift into the upper normal range. The number of @entity1 with elevated serum-creatinin-levels increased during SB-treatment whereas the opposite was noted with SF. This could be due to @entity1483 's positive effects on renal functions.

[Comparative study of 2 diuretic-containing combination preparations in @entity1 with XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure'] @entity69718 :: ('MESH:C009732', 'Chemical') :: ['butizide'] @entity1483 :: ('MESH:D005665', 'Chemical') :: ['furosemide'] @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium'] @entity291 :: ('9913', 'Species') :: ['calf'] @entity1482 :: ('MESH:D013148', 'Chemical') :: ['spironolactone']
@entity712 :: (MESH:D006333,Disease) :: ['edematous heart failure']
